A Short Review on Anti-diabetics for Uncontrolled Type 2 Diabetes Mellitus

Authors

  • Hussain Ahmad Assistant Professor, Department of Pharmacology & Therapeutics, Sylhet Women’s Medical College, Sylhet
  • Md Abu Nayeem Chowdhury Professor, Department of Pharmacology & Therapeutics, Sylhet Women’s Medical College, Sylhet

DOI:

https://doi.org/10.3329/medtoday.v31i2.41966

Keywords:

Type 2 diabetes mellitus, Diagnosis, Management, Newer drugs

Abstract

Introduction: This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade. Materials and Methods: This review is based on a search of Medline, the Cochrane Database of Systemic Reviews, and citation lists of relevant publications. Subject heading and key words used include type 2 diabetes mellitus, prevalence, current diagnosis, and current treatment. Only articles in English were included.

Materials & Methods: Screening and diagnosis is still based on World Health Organization (WHO) and American Diabetes Association (ADA) criteria which include both clinical and laboratory parameters. No cure has yet been found for the disease; however, treatment modalities include lifestyle modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers is still the recommended first line medication. Other effective medications include non-sulfonylurea secretagogues, thiazolidinediones, alpha glucosidase inhibitors, and insulin. Recent research into the pathophysiology of type 2 DM has led to the introduction of new medications like glucagon-like peptide 1 analogoues: dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter 2 and 11ß-hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine.

Discussion: Screening and diagnosis is still based on World Health Organization (WHO) and American Diabetes Association (ADA) criteria which include both clinical and laboratory parameters. No cure has yet been found for the disease; however, treatment modalities include lifestyle modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers is still the recommended first line medication. Other effective medications include non-sulfonylurea secretagogues, thiazolidinediones, alpha glucosidase inhibitors, and insulin. Recent research into the pathophysiology of type 2 DM has led to the introduction of new medications like glucagon-like peptide 1 analogoues: dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter 2 and 11ß-hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine.

Conclusion: Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on the characteristics of each patient.

Medicine Today 2019 Vol.31(2): 120-127

Downloads

Download data is not yet available.
Abstract
954
PDF
895

Downloads

Published

2019-06-26

How to Cite

Ahmad, H., & Chowdhury, M. A. N. (2019). A Short Review on Anti-diabetics for Uncontrolled Type 2 Diabetes Mellitus. Medicine Today, 31(2), 120–127. https://doi.org/10.3329/medtoday.v31i2.41966

Issue

Section

Review Articles